Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 169Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Recurrence 28Leukemia 24Vomiting 23Neoplasms, Plasma Cell 20Lymphoma 18Neoplasms 16Nausea 13Burkitt Lymphoma 11Prostatic Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Follicular 5Lung Neoplasms 5Hodgkin Disease 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Paraproteinemias 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

Cyclophosphamide 3Epirubicin 2Docetaxel 2Carboplatin 2Capecitabine 2Azacitidine 2venetoclax 1tegafur-gimeracil-oteracil 1taxane 1sargramostim 1ruxolitinib 1rucaparib 1pirarubicin 1pertuzumab 1pembrolizumab 1olaparib 1cc-486 1Trastuzumab 1Thalidomide 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Oxaliplatin 1Observation 1Nivolumab 1Monatide (IMS 3015) 1Methotrexate 1Magnetic Resonance Imaging 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pathologic Complete Response × Dexamethasone × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡